EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino

Boston, November 11 (ots/PRNewswire) - EvaluatePharma USA, Inc.
the online analysis service for the global biotechnology and
pharmaceutical sector, was welcomed into Boston's biotech community
today by Mayor Menino at the opening of their new office in Boston,
the #1 life sciences cluster in the US.

Senior Vice President Debbie Paul said, "EvaluatePharma USA are
very excited to be joining the Boston biotech community with the
opening of our new office at Broad Street. Many of our clients are
based in Boston and we will now be able to work more closely with the
biotech community, supporting them with innovative products and
services designed to help the commercialization of their products."

Commenting at the opening ceremony, Dr. Jonathan de Pass, CEO and
Founder said "We are very grateful to Mayor Menino and the LifeTech
programme for their help and support in the opening of this new
office. EvaluatePharma is committed to developing new products and
services that continue to support the biotech community such as the
launch of our new service Partnering Opportunities. By registering
their licensing assets with our Partnering Opportunities the biotech
community can reach our global audience of business development and
licensing professionals across the world's leading pharma companies."

EvaluatePharma's Partnering Opportunities is a new free service
that allows potential partners to see the latest opportunities from
the biotech community in their commercial context alongside
EvaluatePharma's industry analysis, including product portfolios,
company financials and reference deal terms.

Founded in 1996 by Dr. Jonathan de Pass, a former top-ranked
Pharmaceutical analyst in the City of London, EvaluatePharma(R)
provides proprietary insights into the commercial and financial
prospects of the pharma and biotech industry and was the first
company to provide reliable consensus forecasts of global drug sales.
Analyses range from total market sales trends and therapeutic
overviews to individual company financial performance and product
progress.

EvaluatePharma's client base includes the top global pharma and
biotech companies, the investment banking community and the leading
global management consulting firms.

Notes to editors

About EvaluatePharma:

The research company EvaluatePharma was the first to supply
reliable consensus forecasts of global drug sales and now provides
standardised worldwide financial and forecast models with consensus
product sales forecasts to 2016, data on R&D pipelines, licensing
deals, patent risk and M&A activity. Launched in 2007,
EvaluatePharma(R)Alpha offers a Net Present Value (NPV) valuation
service quantifying market events and the impact on product,
portfolio and company valuation including the daily online news
service EP Vantage(R).

EvaluatePharma(R), EvaluatePharma(R)Alpha, and EP Vantage(R) are
services of EvaluatePharma Ltd, headquartered in London, England. In
North America, EvaluatePharma Ltd is represented by

EvaluatePharma USA, Inc.

http://www.evaluatepharma.com

Contact:
Debbie Paul
Senior Vice President, North America
T: +1-866-806-1309
E: debbiep@evaluatepharma.com
EvaluatePharma USA, Inc.
15 Broad Street, Suite 401
Boston, MA 02109
USA
Andrew Beaven
Marketing Director, EvaluatePharma Ltd
T: +44(0)20-7539-1818
E: andrewb@evaluatepharma.com
EvaluatePharma Ltd
11-29 Fashion Street
London
E1 6PX
United Kingdom

ots Originaltext: EvaluatePharma Ltd
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Contact: Debbie Paul, Senior Vice President, North America,
T:+1-866-806-1309, E: debbiep@evaluatepharma.com ; EvaluatePharma
USA, Inc.,15 Broad Street, Suite 401, Boston, MA 02109, USA. Andrew
Beaven, MarketingDirector, EvaluatePharma Ltd, T: +44(0)20-7539-1818,
E:andrewb@evaluatepharma.com ; EvaluatePharma Ltd, 11-29 Fashion
Street,London, E1 6PX, United Kingdom.